Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 3, 2023

CLINICAL TRIALS PROFILE FOR ZONISAMIDE

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Zonisamide

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00047567 ↗	Open-label Adjunctive Zonisamide for Bipolar Disorder	Terminated	Elan Pharmaceuticals	Phase 4	2002-07-01	To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
NCT00055484 ↗	A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache	Completed	Elan Pharmaceuticals	Phase 2	2002-03-01	The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache.
NCT00056576 ↗	Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy	Completed	Eisai Inc.	Phase 3	2002-02-01	The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
NCT00068770 ↗	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT	Terminated	National Cancer Institute (NCI)	Phase 2	2003-10-01	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Zonisamide

Condition Name

Chart
Table

Condition Name for Zonisamide
Intervention	Trials
Epilepsy	17
Obesity	6
Healthy	6
Alcohol Dependence	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Zonisamide
Intervention	Trials
Epilepsy	15
Seizures	14
Alcoholism	11
Disease	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Zonisamide

Trials by Country

Map
Table

Trials by Country for Zonisamide
Location	Trials
United States	107
India	12
Australia	11
Germany	10
Italy	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Zonisamide
Location	Trials
Massachusetts	7
North Carolina	7
Connecticut	6
Alabama	6
Ohio	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Zonisamide

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Zonisamide
Clinical Trial Phase	Trials
Phase 4	16
Phase 3	18
Phase 2/Phase 3	1
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Zonisamide
Clinical Trial Phase	Trials
Completed	42
Terminated	13
Withdrawn	4
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zonisamide

Sponsor Name

Chart
Table

Sponsor Name for Zonisamide
Sponsor	Trials
Eisai Inc.	15
Eisai Limited	6
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	4
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Zonisamide
Sponsor	Trials
Other	63
Industry	46
NIH	9
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Medtronic

Moodys

McKinsey

Baxter

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.